VyvgartActive Ingredient(s): Efgartigimod Alfa
FDA Approved: * December 17, 2021
Pharm Company: * ARGENX BV
Efgartigimod alfa, sold under the brand name Vyvgart, is a medication used to treat myasthenia gravis. The most common side effects include respiratory tract infections, headache, and urinary tract infections. Efgartigimod alfa is a neonatal Fc receptor blocker and is a new class of medication. It is an antibody fragment that binds to the neonatal Fc receptor (FcRn), preventing FcRn from recycling immunoglobulin G (Ig... [wikipedia]* May have multiple approval dates, manufacturers, or labelers.